Oppenheimer reaffirmed their outperform rating on shares of BioTime, Inc. (NYSEMKT:BTX) in a research note published on Monday morning, Market Beat.com reports. They currently have a $10.00 price target on the biotechnology company’s stock.

Shares of BioTime (NYSEMKT:BTX) opened at 2.40 on Monday. BioTime has a 1-year low of $2.20 and a 1-year high of $5.95. The stock has a 50 day moving average price of $3.24 and a 200-day moving average price of $3.35. The company’s market cap is $196.91 million.

In other BioTime news, Director Stephen C. Farrell purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The shares were acquired at an average cost of $3.83 per share, for a total transaction of $191,500.00. Following the transaction, the director now directly owns 97,450 shares in the company, valued at $373,233.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Broadwood Partners Lp purchased 300,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 20th. The shares were acquired at an average price of $2.35 per share, for a total transaction of $705,000.00. The disclosure for this purchase can be found here.

BioTime, Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (NYSEMKT:BTX) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines, including tissue banking, cellular therapy, gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases, such as neurological disorders, cancer, age related macular degeneration, orthopedic disorders, and age-related cardiovascular disease.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.